Drug · CHEMBL1714
KETAMINE HYDROCHLORIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. KETAMINE HYDROCHLORIDE. Drugs and targets, record CHEMBL1714. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1714
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- CI-581, CL 369, CL-369, CN-52,372-2, CN-52372-2, CN-523722, Ketamine (as hydrochloride), Ketamine hcl, Ketamine hydrochloride ciii, Ketamini hydrochloridum, Special k, Vetalar
- ChEMBL
Targets7
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| GRIN1 | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2902 |
| GRIN2A | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2903 |
| GRIN2B | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2904 |
| GRIN2C | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2905 |
| GRIN2D | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2906 |
| GRIN3A | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/116443 |
| GRIN3B | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/116444 |
Source ChEMBL
Diseases19
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 19Source Open Targets
See all 19 diseasesTrials53
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03621085 | Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine | Phase 4 | 43 | 2021-11-26 | ketamine hydrochloride | Its name | ClinicalTrials.gov |
| NCT05796791 | Ketamine and Motivational Enhancement Therapy for the Treatment of Tobacco Use Disorder | Early phase 1 | 7 | 2025-07-18 | ketamine hydrochloride | Its name | ClinicalTrials.gov |
| NCT05437575 | Prehospital Analgesia INtervention Trial (PAIN) | Phase 3 | 994 | ketamine hydrochloride | Its name | ClinicalTrials.gov | |
| NCT05468047 | Ketamine Therapy Experiential Education Study | Early phase 1 | 500 | ketamine hydrochloride | Its name | ClinicalTrials.gov | |
| NCT07558044 | Ketamine Gargle for Pain After Pediatric Tonsillectomy | Phase 4 | 420 | ketamine hydrochloride | Its name | ClinicalTrials.gov | |
| NCT01316744 | Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain | Phase 3 | 214 | ketamine hydrochloride | Its name | ClinicalTrials.gov | |
| NCT04658420 | A Single Ketamine Infusion Combined With Music for Suicidal Ideation | Phase 2 | 200 | ketamine hydrochloride | Its name | ClinicalTrials.gov | |
| NCT03396601 | NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression | Phase 3 | 150 | ketamine hydrochloride | Its name | ClinicalTrials.gov | |
| NCT04490031 | Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP) | Phase 4 | 140 | ketamine hydrochloride | Its name | ClinicalTrials.gov | |
| NCT05962424 | HNC: Human Neural Circuits Electrophysiology During Cognition | Phase 1 | 120 | ketamine hydrochloride | Its name | ClinicalTrials.gov |
1 to 10 of 53
See all 53 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ketamine vs Placebo: deaths from any cause | 0 of 30 | 0 of 30 | 60 | NCT03621085 | Trial comparisons |
| Ketamine vs Placebo: serious adverse events | 0 of 30 | 0 of 30 | 60 | NCT03621085 | Trial comparisons |
Papers from its trials16
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials9
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Choice Reaction Time | 1 | 0 | ConductCognition |
| Implicit Association Test (IAT) | 1 | 0 | ConductCognition |
| Recognition Memory Test | 1 | 0 | ConductCognition |
| Symbol Coding | 1 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
| Trail Making Test B | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1714
GET https://conductscience.org/api/drugs/v1/CHEMBL1714/trials?page=2